Brief: Biocept And Protean BioDiagnostics Establish Research Collaboration To Demonstrate Advantages Of Biocept’s Target Selector Assay Kit For Non-Small Cell Lung Cancer Patients
23/02/2021 13:18
Feb 23 (Reuters) - Biocept Inc BIOC.O :
* BIOCEPT AND PROTEAN BIODIAGNOSTICS ESTABLISH RESEARCH
COLLABORATION TO DEMONSTRATE ADVANTAGES OF BIOCEPT’S TARGET
SELECTOR™ ASSAY KIT FOR NON-SMALL CELL LUNG CANCER PATIENTS
Source text for Eikon: ID:nBw7qWZfBa
Further company coverage: BIOC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biocept
See all newsBrief: Biocept Says Trading Of Common Stock Will Be Suspended By Nasdaq At Opening Of Business On Oct 25
U.S. STOCKS ON THE MOVE-Overstock.com, Biocept, Birkenstock
Biocept slumps after filing for bankruptcy protection
Brief: Biocept CEO Antonino Morales Resigns
U.S. STOCKS ON THE MOVE-Albemarle, Novavax, WeWork